Plus Therapeutics, Inc. (PSTV)
USD 0.79
(1.94%)
USD 0.79
(1.94%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 85 Thousand USD | -97.84% |
| 2022 | 3.92 Million USD | -25.54% |
| 2021 | 5.27 Million USD | 898.86% |
| 2020 | 528 Thousand USD | -18.27% |
| 2019 | 646 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 11 Million USD | -34.01% |
| 2015 | 16.68 Million USD | -7.54% |
| 2014 | 18.04 Million USD | -21.9% |
| 2013 | 23.1 Million USD | 79.03% |
| 2012 | 12.9 Million USD | -41.25% |
| 2011 | 21.96 Million USD | 65.69% |
| 2010 | 13.25 Million USD | 375.09% |
| 2009 | 2.79 Million USD | -44.69% |
| 2008 | 5.04 Million USD | 2028.27% |
| 2007 | 237 Thousand USD | -79.55% |
| 2006 | 1.15 Million USD | -25.61% |
| 2005 | 1.55 Million USD | 38.12% |
| 2004 | 1.12 Million USD | -2.51% |
| 2003 | 1.15 Million USD | 50.26% |
| 2002 | 770 Thousand USD | -60.02% |
| 2001 | 1.92 Million USD | 655.29% |
| 2000 | 255 Thousand USD | 0.0% |
| 1999 | - USD | -100.0% |
| 1998 | 209 Thousand USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 59 Thousand USD | 0.0% |
| 2024 Q2 | 50 Thousand USD | 0.0% |
| 2023 FY | 85 Thousand USD | -97.84% |
| 2023 Q1 | 166 Thousand USD | -95.77% |
| 2023 Q3 | 118 Thousand USD | -13.24% |
| 2023 Q4 | 85 Thousand USD | -27.97% |
| 2023 Q2 | 136 Thousand USD | -18.07% |
| 2022 Q1 | 4.95 Million USD | -6.09% |
| 2022 Q3 | 4.28 Million USD | -7.38% |
| 2022 Q4 | 3.92 Million USD | -8.25% |
| 2022 FY | 3.92 Million USD | -25.54% |
| 2022 Q2 | 4.62 Million USD | -6.7% |
| 2021 FY | 5.27 Million USD | 898.86% |
| 2021 Q3 | 504 Thousand USD | -4.91% |
| 2021 Q2 | 530 Thousand USD | 5.37% |
| 2021 Q1 | 503 Thousand USD | -4.73% |
| 2021 Q4 | 5.27 Million USD | 946.43% |
| 2020 FY | 528 Thousand USD | -18.27% |
| 2020 Q4 | 528 Thousand USD | -3.12% |
| 2020 Q1 | 624 Thousand USD | -3.41% |
| 2020 Q2 | 589 Thousand USD | -5.61% |
| 2020 Q3 | 545 Thousand USD | -7.47% |
| 2019 Q2 | 748 Thousand USD | -50.72% |
| 2019 Q3 | 684 Thousand USD | -8.56% |
| 2019 Q4 | 646 Thousand USD | -5.56% |
| 2019 FY | 646 Thousand USD | 0.0% |
| 2019 Q1 | 1.51 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q2 | 7.77 Million USD | -17.33% |
| 2017 Q1 | 9.4 Million USD | -14.61% |
| 2016 Q3 | 12.13 Million USD | -11.22% |
| 2016 Q2 | 13.66 Million USD | -10.1% |
| 2016 Q1 | 15.19 Million USD | -8.89% |
| 2016 Q4 | 11 Million USD | -9.25% |
| 2016 FY | 11 Million USD | -34.01% |
| 2015 FY | 16.68 Million USD | -7.54% |
| 2015 Q2 | 16.18 Million USD | 3.23% |
| 2015 Q1 | 15.67 Million USD | -13.1% |
| 2015 Q4 | 16.68 Million USD | 11.37% |
| 2015 Q3 | 14.97 Million USD | -7.45% |
| 2014 Q2 | 19.5 Million USD | -8.55% |
| 2014 FY | 18.04 Million USD | -21.9% |
| 2014 Q4 | 18.04 Million USD | -11.27% |
| 2014 Q3 | 20.33 Million USD | 4.26% |
| 2014 Q1 | 21.32 Million USD | -7.68% |
| 2013 Q3 | 24.82 Million USD | -3.49% |
| 2013 Q1 | 10.59 Million USD | -17.9% |
| 2013 FY | 23.1 Million USD | 79.03% |
| 2013 Q2 | 25.71 Million USD | 142.77% |
| 2013 Q4 | 23.1 Million USD | -6.94% |
| 2012 FY | 12.9 Million USD | -41.25% |
| 2012 Q4 | 12.9 Million USD | -14.99% |
| 2012 Q3 | 15.17 Million USD | -12.98% |
| 2012 Q1 | 19.7 Million USD | -10.28% |
| 2012 Q2 | 17.44 Million USD | -11.48% |
| 2011 Q4 | 21.96 Million USD | -9.28% |
| 2011 FY | 21.96 Million USD | 65.69% |
| 2011 Q1 | 11.32 Million USD | -14.59% |
| 2011 Q3 | 24.2 Million USD | 160.45% |
| 2011 Q2 | 9.29 Million USD | -17.9% |
| 2010 Q2 | 17.22 Million USD | 698.98% |
| 2010 Q4 | 13.25 Million USD | -13.04% |
| 2010 Q1 | 2.15 Million USD | -22.72% |
| 2010 Q3 | 15.24 Million USD | -11.51% |
| 2010 FY | 13.25 Million USD | 375.09% |
| 2009 Q3 | 3.39 Million USD | -14.47% |
| 2009 Q1 | 4.52 Million USD | -10.39% |
| 2009 FY | 2.79 Million USD | -44.69% |
| 2009 Q4 | 2.79 Million USD | -17.92% |
| 2009 Q2 | 3.97 Million USD | -12.08% |
| 2008 FY | 5.04 Million USD | 2028.27% |
| 2008 Q1 | 184 Thousand USD | -22.36% |
| 2008 Q4 | 5.04 Million USD | 4403.57% |
| 2008 Q2 | 129 Thousand USD | -29.89% |
| 2008 Q3 | 112 Thousand USD | -13.18% |
| 2007 Q1 | 956 Thousand USD | -17.52% |
| 2007 Q3 | 444 Thousand USD | -27.57% |
| 2007 Q2 | 613 Thousand USD | -35.88% |
| 2007 Q4 | 237 Thousand USD | -46.62% |
| 2007 FY | 237 Thousand USD | -79.55% |
| 2006 Q2 | 2.01 Million USD | 51.01% |
| 2006 Q4 | 1.15 Million USD | 27.36% |
| 2006 Q3 | 910 Thousand USD | -54.93% |
| 2006 Q1 | 1.33 Million USD | -14.18% |
| 2006 FY | 1.15 Million USD | -25.61% |
| 2005 Q2 | 819 Thousand USD | -16.09% |
| 2005 FY | 1.55 Million USD | 38.12% |
| 2005 Q4 | 1.55 Million USD | 136.78% |
| 2005 Q1 | 976 Thousand USD | -13.48% |
| 2005 Q3 | 658 Thousand USD | -19.66% |
| 2004 FY | 1.12 Million USD | -2.51% |
| 2004 Q1 | 1.44 Million USD | 24.89% |
| 2004 Q2 | 1.32 Million USD | -8.1% |
| 2004 Q4 | 1.12 Million USD | -16.26% |
| 2004 Q3 | 1.34 Million USD | 1.43% |
| 2003 Q3 | 829 Thousand USD | 42.69% |
| 2003 Q4 | 1.15 Million USD | 39.57% |
| 2003 Q2 | 581 Thousand USD | -15.92% |
| 2003 FY | 1.15 Million USD | 50.26% |
| 2003 Q1 | 691 Thousand USD | -10.26% |
| 2002 Q4 | 770 Thousand USD | -26.67% |
| 2002 Q2 | 1.62 Million USD | -9.82% |
| 2002 Q3 | 1.05 Million USD | -35.38% |
| 2002 FY | 770 Thousand USD | -60.02% |
| 2002 Q1 | 1.8 Million USD | -6.44% |
| 2001 Q1 | 230 Thousand USD | 0.0% |
| 2001 Q2 | 197 Thousand USD | -14.35% |
| 2001 Q3 | 167 Thousand USD | -15.23% |
| 2001 Q4 | 1.92 Million USD | 1053.29% |
| 2001 FY | 1.92 Million USD | 655.29% |
| 2000 FY | 255 Thousand USD | 0.0% |
| 1999 FY | - USD | -100.0% |
| 1998 FY | 209 Thousand USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | 71.22 Million USD | 99.881% |
| Alkermes plc | 287.73 Million USD | 99.97% |
| Agenus Inc. | 137.32 Million USD | 99.938% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 99.996% |
| Aptorum Group Limited | 3.05 Million USD | 97.221% |
| Ardelyx, Inc. | 51.54 Million USD | 99.835% |
| Arrowhead Pharmaceuticals, Inc. | 104.6 Million USD | 99.919% |
| Bicycle Therapeutics plc | 40.08 Million USD | 99.788% |
| BioXcel Therapeutics, Inc. | 100.59 Million USD | 99.916% |
| ChromaDex Corporation | 2.57 Million USD | 96.699% |
| Chimerix, Inc. | 125 Thousand USD | 32.0% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | 97.375% |
| Caribou Biosciences, Inc. | 25.9 Million USD | 99.672% |
| CRISPR Therapeutics AG | 223 Million USD | 99.962% |
| Precision BioSciences, Inc. | 7.72 Million USD | 98.899% |
| Dyadic International, Inc. | 88.87 Thousand USD | 4.355% |
| Eton Pharmaceuticals, Inc. | 22 Thousand USD | -286.364% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.86% |
| Lantern Pharma Inc. | 61.49 Thousand USD | -38.22% |
| HOOKIPA Pharma Inc. | 3.8 Million USD | 97.764% |
| Inhibikase Therapeutics, Inc. | 90.12 Thousand USD | 5.685% |
| Incyte Corporation | 29.16 Million USD | 99.709% |
| IO Biotech, Inc. | 1.83 Million USD | 95.378% |
| Jaguar Health, Inc. | 30.99 Million USD | 99.726% |
| Novavax, Inc. | 168.01 Million USD | 99.949% |
| Janux Therapeutics, Inc. | 23.02 Million USD | 99.631% |
| Opthea Limited | 200.53 Million USD | 99.958% |
| Ligand Pharmaceuticals Incorporated | 5.75 Million USD | 98.523% |
| ContextLogic Inc. | 6 Million USD | 98.583% |
| MiMedx Group, Inc. | 48.09 Million USD | 99.823% |
| Pyxis Oncology, Inc. | 20.09 Million USD | 99.577% |
| TransCode Therapeutics, Inc. | 38.29 Thousand USD | -121.984% |
| NextCure, Inc. | 5.94 Million USD | 98.571% |
| Ocuphire Pharma, Inc. | - USD | -Infinity% |
| Oncternal Therapeutics, Inc. | 145 Thousand USD | 41.379% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Vaxcyte, Inc. | 22.11 Million USD | 99.616% |
| PDS Biotechnology Corporation | 19.5 Million USD | 99.564% |
| Madrigal Pharmaceuticals, Inc. | 115.48 Million USD | 99.926% |
| Pharming Group N.V. | 166.1 Million USD | 99.949% |
| Pieris Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avidity Biosciences, Inc. | 6.21 Million USD | 98.632% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | 99.746% |
| Sol-Gel Technologies Ltd. | 1.2 Million USD | 92.952% |
| Acelyrin, Inc. | 1.19 Million USD | 92.881% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | 460 Thousand USD | 81.522% |
| Summit Therapeutics Inc. | 103.29 Million USD | 99.918% |
| Sensei Biotherapeutics, Inc. | 3.76 Million USD | 97.745% |
| Senti Biosciences, Inc. | 33.53 Million USD | 99.747% |
| Stoke Therapeutics, Inc. | 4.77 Million USD | 98.219% |
| Syros Pharmaceuticals, Inc. | 34.55 Million USD | 99.754% |
| Alaunos Therapeutics, Inc. | - USD | -Infinity% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Entrada Therapeutics, Inc. | 60.32 Million USD | 99.859% |
| VistaGen Therapeutics, Inc. | 1.57 Million USD | 94.586% |
| Wave Life Sciences Ltd. | 25.4 Million USD | 99.665% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 99.919% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | 88.388% |
| Barinthus Biotherapeutics plc | 11.19 Million USD | 99.24% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Phathom Pharmaceuticals, Inc. | 138.3 Million USD | 99.939% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 13.43 Million USD | 99.368% |
| MEI Pharma, Inc. | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | 15 Million USD | 99.433% |
| Xeris Biopharma Holdings, Inc. | 190.93 Million USD | 99.955% |
| Rigel Pharmaceuticals, Inc. | 52.65 Million USD | 99.839% |
| Fortress Biotech, Inc. | 60.85 Million USD | 99.86% |
| Precigen, Inc. | 5.89 Million USD | 98.558% |
| Clearside Biomedical, Inc. | 41.98 Million USD | 99.798% |
| AlloVir, Inc. | 16.64 Million USD | 99.489% |
| C4 Therapeutics, Inc. | 65.75 Million USD | 99.871% |
| Fate Therapeutics, Inc. | 97.36 Million USD | 99.913% |
| ImmuCell Corporation | 10.54 Million USD | 99.194% |
| IDEAYA Biosciences, Inc. | 1.12 Million USD | 92.444% |
| Onconetix, Inc. | 118.85 Thousand USD | 28.485% |
| PureTech Health plc | 18.25 Million USD | 99.534% |
| VYNE Therapeutics Inc. | 99 Thousand USD | 14.141% |
| Elevation Oncology, Inc. | 30.13 Million USD | 99.718% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 25.96 Million USD | 99.673% |
| Verrica Pharmaceuticals Inc. | 42.87 Million USD | 99.802% |
| Innoviva, Inc. | 446.23 Million USD | 99.981% |
| Aadi Bioscience, Inc. | 833 Thousand USD | 89.796% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| GlycoMimetics, Inc. | 66.84 Thousand USD | -27.162% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 206.96 Million USD | 99.959% |
| Akebia Therapeutics, Inc. | 71.19 Million USD | 99.881% |
| Catalyst Pharmaceuticals, Inc. | 3.18 Million USD | 97.334% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 1.03 Million USD | 91.811% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | 22.32 Million USD | 99.619% |
| Aptose Biosciences Inc. | 621 Thousand USD | 86.312% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 1.01 Million USD | 91.592% |
| Century Therapeutics, Inc. | 46.65 Million USD | 99.818% |
| Kura Oncology, Inc. | 9.33 Million USD | 99.089% |
| TScan Therapeutics, Inc. | 26.7 Million USD | 99.682% |
| Intensity Therapeutics, Inc. | 138 Thousand USD | 38.406% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 9.38 Million USD | 99.094% |
| Autolus Therapeutics plc | 47.91 Million USD | 99.823% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 4.9 Million USD | 98.267% |
| Eterna Therapeutics Inc. | 6.77 Million USD | 98.745% |
| Adaptive Biotechnologies Corporation | 130.66 Million USD | 99.935% |
| GRI Bio, Inc. | - USD | -Infinity% |
| Xenetic Biosciences, Inc. | - USD | -Infinity% |
| Tenaya Therapeutics, Inc. | 8.1 Million USD | 98.951% |
| IGM Biosciences, Inc. | 34.67 Million USD | 99.755% |
| INmune Bio, Inc. | 397 Thousand USD | 78.589% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 99.951% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 97.903% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | 146.94 Thousand USD | 42.157% |
| Milestone Pharmaceuticals Inc. | 49.77 Million USD | 99.829% |
| X4 Pharmaceuticals, Inc. | 54.57 Million USD | 99.844% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 99.814% |
| Coherus BioSciences, Inc. | 473.36 Million USD | 99.982% |
| Verastem, Inc. | 40.08 Million USD | 99.788% |
| Abeona Therapeutics Inc. | 4.4 Million USD | 98.069% |
| Pliant Therapeutics, Inc. | 10.05 Million USD | 99.155% |
| Tonix Pharmaceuticals Holding Corp. | 6.56 Million USD | 98.704% |
| Histogen Inc. | 4.38 Million USD | 98.061% |
| Aprea Therapeutics, Inc. | - USD | -Infinity% |
| Surrozen, Inc. | 882 Thousand USD | 90.363% |
| Organovo Holdings, Inc. | 888 Thousand USD | 90.428% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 30 Million USD | 99.717% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | 97.973% |
| CASI Pharmaceuticals, Inc. | 18.89 Million USD | 99.55% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 75.7 Million USD | 99.888% |
| Hepion Pharmaceuticals, Inc. | 93.1 Thousand USD | 8.704% |
| Arcturus Therapeutics Holdings Inc. | 25.9 Million USD | 99.672% |
| BioRestorative Therapies, Inc. | - USD | -Infinity% |
| Apollomics, Inc. | 267 Thousand USD | 68.165% |
| Amarin Corporation plc | 8.73 Million USD | 99.027% |
| Mesoblast Limited | 100.48 Million USD | 99.915% |
| Turnstone Biologics Corp. | 1.18 Million USD | 92.851% |
| Kymera Therapeutics, Inc. | 78.32 Million USD | 99.891% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | 109 Thousand USD | 22.018% |
| Aurinia Pharmaceuticals Inc. | 82 Million USD | 99.896% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 189.94 Million USD | 99.955% |
| Better Therapeutics, Inc. | 10.34 Million USD | 99.179% |
| Nurix Therapeutics, Inc. | 23.12 Million USD | 99.632% |
| Apellis Pharmaceuticals, Inc. | 93.03 Million USD | 99.909% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | 93.421% |
| Gritstone bio, Inc. | 40.14 Million USD | 99.788% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 95.314% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 153.59 Million USD | 99.945% |
| Insmed Incorporated | 1.19 Billion USD | 99.993% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 6.35 Million USD | 98.661% |
| OmniAb, Inc. | 22.07 Million USD | 99.615% |
| Alector, Inc. | 30.45 Million USD | 99.721% |
| Seres Therapeutics, Inc. | 101.54 Million USD | 99.916% |
| Checkpoint Therapeutics, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Zai Lab Limited | 8.04 Million USD | 98.944% |
| Revance Therapeutics, Inc. | 426.59 Million USD | 99.98% |
| Aura Biosciences, Inc. | 16.87 Million USD | 99.496% |
| Lyell Immunopharma, Inc. | 56.89 Million USD | 99.851% |
| Immunic, Inc. | 639 Thousand USD | 86.698% |
| Tarsus Pharmaceuticals, Inc. | 29.81 Million USD | 99.715% |
| Veracyte, Inc. | 7.52 Million USD | 98.87% |
| InMed Pharmaceuticals Inc. | 644.86 Million USD | 99.987% |
| FibroGen, Inc. | 89.69 Million USD | 99.905% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 98.04% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 130.86 Thousand USD | 35.047% |
| Jazz Pharmaceuticals plc | 5.1 Billion USD | 99.998% |
| Cyclacel Pharmaceuticals, Inc. | 37 Thousand USD | -129.73% |
| Amylyx Pharmaceuticals, Inc. | 1.98 Million USD | 95.707% |
| TG Therapeutics, Inc. | 100.11 Million USD | 99.915% |
| Galecto, Inc. | 66 Thousand USD | -28.788% |
| Calithera Biosciences, Inc. | 136 Thousand USD | 37.5% |
| Fortrea Holdings Inc. | 1.63 Billion USD | 99.995% |
| KalVista Pharmaceuticals, Inc. | 6.01 Million USD | 98.587% |
| Aptevo Therapeutics Inc. | 5.39 Million USD | 98.425% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | 1.81 Million USD | 95.314% |
| Lyra Therapeutics, Inc. | 21.44 Million USD | 99.604% |
| Foghorn Therapeutics Inc. | 36.55 Million USD | 99.767% |
| Y-mAbs Therapeutics, Inc. | 517 Thousand USD | 83.559% |
| Theravance Biopharma, Inc. | 45.23 Million USD | 99.812% |
| Ultragenyx Pharmaceutical Inc. | 30.57 Million USD | 99.722% |
| Metagenomi, Inc. Common Stock | 44.8 Million USD | 99.81% |
| Vaxxinity, Inc. | 13.26 Million USD | 99.359% |
| BioCryst Pharmaceuticals, Inc. | 811.26 Million USD | 99.99% |
| Gain Therapeutics, Inc. | 449.05 Thousand USD | 81.071% |
| Cartesian Therapeutics, Inc. | 8.78 Million USD | 99.033% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | - USD | -Infinity% |
| Marker Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 99.997% |
| Chemomab Therapeutics Ltd. | 316 Thousand USD | 73.101% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | 4.45 Million USD | 98.093% |
| Ainos, Inc. | 5.92 Million USD | 98.565% |
| Pluri Inc. | 29.05 Million USD | 99.707% |
| Prothena Corporation plc | 10.72 Million USD | 99.207% |
| Adaptimmune Therapeutics plc | 19.85 Million USD | 99.572% |
| Celularity Inc. | 26.17 Million USD | 99.675% |
| Rallybio Corporation | 173 Thousand USD | 50.867% |
| Cue Biopharma, Inc. | 4.2 Million USD | 97.977% |
| MeiraGTx Holdings plc | 72.11 Million USD | 99.882% |
| Omeros Corporation | 329.7 Million USD | 99.974% |
| Humacyte, Inc. | 38.6 Million USD | 99.78% |
| Immunocore Holdings plc | 82.64 Million USD | 99.897% |
| Cocrystal Pharma, Inc. | 1.61 Million USD | 94.73% |
| Cidara Therapeutics, Inc. | 3.57 Million USD | 97.624% |
| Blueprint Medicines Corporation | 610.96 Million USD | 99.986% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | 1.45 Million USD | 94.17% |
| Marinus Pharmaceuticals, Inc. | 95.18 Million USD | 99.911% |
| Scholar Rock Holding Corporation | 48.68 Million USD | 99.825% |
| Sana Biotechnology, Inc. | 90.9 Million USD | 99.906% |
| Pulmatrix, Inc. | 8.32 Million USD | 98.979% |
| Elicio Therapeutics, Inc. | 6 Million USD | 98.585% |
| Vigil Neuroscience, Inc. | 12.94 Million USD | 99.343% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 99.912% |
| Adlai Nortye Ltd. American Depositary Shares | 469 Thousand USD | 81.876% |
| Cytokinetics, Incorporated | 607.37 Million USD | 99.986% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | 99.022% |
| Nutriband Inc. | 79.82 Thousand USD | -6.482% |
| Protara Therapeutics, Inc. | 4.48 Million USD | 98.104% |
| Vor Biopharma Inc. | 31.83 Million USD | 99.733% |
| Roivant Sciences Ltd. | 477.85 Million USD | 99.982% |
| Evogene Ltd. | 10.65 Million USD | 99.202% |
| ProKidney Corp. | 3.61 Million USD | 97.645% |
| Applied Therapeutics, Inc. | 759 Thousand USD | 88.801% |
| Hoth Therapeutics, Inc. | 26.32 Thousand USD | -222.875% |
| BridgeBio Pharma, Inc. | 1.73 Billion USD | 99.995% |
| CorMedix Inc. | 517.01 Thousand USD | 83.559% |
| BioLineRx Ltd. | 6.62 Million USD | 98.718% |
| Tango Therapeutics, Inc. | 36.83 Million USD | 99.769% |
| Galectin Therapeutics Inc. | 71.74 Million USD | 99.882% |
| Atai Life Sciences N.V. | 15.21 Million USD | 99.441% |
| Renovaro Biosciences Inc. | 842.38 Thousand USD | 89.91% |
| Aerovate Therapeutics, Inc. | 255 Thousand USD | 66.667% |
| Zentalis Pharmaceuticals, Inc. | 43.15 Million USD | 99.803% |
| Sagimet Biosciences Inc. | - USD | -Infinity% |
| MediciNova, Inc. | 410.66 Thousand USD | 79.302% |
| Praxis Precision Medicines, Inc. | 1.36 Million USD | 93.791% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 87.181% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 99.952% |
| Biomea Fusion, Inc. | 7.83 Million USD | 98.914% |
| PTC Therapeutics, Inc. | 284.21 Million USD | 99.97% |
| Mereo BioPharma Group plc | 5.3 Million USD | 98.396% |
| Cullinan Oncology, Inc. | 2.15 Million USD | 96.047% |
| Syndax Pharmaceuticals, Inc. | 588 Thousand USD | 85.544% |
| Absci Corporation | 4.66 Million USD | 98.176% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 11.52 Million USD | 99.262% |
| Dyne Therapeutics, Inc. | 22.69 Million USD | 99.625% |
| Kiniksa Pharmaceuticals, Ltd. | 10 Million USD | 99.15% |
| Ventyx Biosciences, Inc. | 11.5 Million USD | 99.261% |
| Allakos Inc. | 38.21 Million USD | 99.778% |
| Imunon, Inc. | 1.13 Million USD | 92.539% |
| Fulcrum Therapeutics, Inc. | 8.62 Million USD | 99.015% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| BioAtla, Inc. | 836 Thousand USD | 89.833% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -750.0% |
| Allogene Therapeutics, Inc. | 88.34 Million USD | 99.904% |
| Larimar Therapeutics, Inc. | 4.7 Million USD | 98.195% |
| XOMA Corporation | 118.51 Million USD | 99.928% |
| Kezar Life Sciences, Inc. | 10.06 Million USD | 99.156% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 99.771% |
| aTyr Pharma, Inc. | 13.76 Million USD | 99.383% |
| Aligos Therapeutics, Inc. | 7.89 Million USD | 98.924% |
| Akero Therapeutics, Inc. | 24.96 Million USD | 99.66% |
| Viridian Therapeutics, Inc. | 20.2 Million USD | 99.579% |
| Eliem Therapeutics, Inc. | 15 Thousand USD | -466.667% |
| EyeGate Pharmaceuticals, Inc. | 278.19 Thousand USD | 69.445% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 99.412% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 99.994% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | 37.579% |
| UroGen Pharma Ltd. | 98.55 Million USD | 99.914% |
| Sutro Biopharma, Inc. | 149.11 Million USD | 99.943% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | 99.554% |
| Entera Bio Ltd. | 256 Thousand USD | 66.797% |
| GH Research PLC | 631 Thousand USD | 86.529% |
| Lisata Therapeutics, Inc. | 137.00 USD | -61943.796% |
| Reneo Pharmaceuticals, Inc. | 642 Thousand USD | 86.76% |
| Xencor, Inc. | 14.64 Million USD | 99.419% |
| 60 Degrees Pharmaceuticals, Inc. | 150.25 Thousand USD | 43.428% |
| Replimune Group, Inc. | 71.99 Million USD | 99.882% |
| Coeptis Therapeutics Holdings, Inc. | 150 Thousand USD | 43.333% |
| Vanda Pharmaceuticals Inc. | 7 Million USD | 98.787% |
| Lexaria Bioscience Corp. | 136.17 Thousand USD | 37.579% |
| Portage Biotech Inc. | 7000.00 USD | -1114.286% |
| Cardio Diagnostics Holdings, Inc. | 663.09 Thousand USD | 87.181% |
| Olema Pharmaceuticals, Inc. | 1.42 Million USD | 94.052% |
| OncoCyte Corporation | 2.2 Million USD | 96.143% |
| Qualigen Therapeutics, Inc. | - USD | -Infinity% |
| Processa Pharmaceuticals, Inc. | 66.9 Thousand USD | -27.046% |
| Purple Biotech Ltd. | 163 Thousand USD | 47.853% |
| CollPlant Biotechnologies Ltd. | 2.53 Million USD | 96.647% |
| scPharmaceuticals Inc. | 38.81 Million USD | 99.781% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | 25.24 Million USD | 99.663% |
| NeuroSense Therapeutics Ltd. | 73 Thousand USD | -16.438% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | 1.85 Million USD | 95.413% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | 26.34 Million USD | 99.677% |
| Curis, Inc. | 1.48 Million USD | 94.291% |
| Daré Bioscience, Inc. | 3.91 Million USD | 97.828% |
| Carmell Therapeutics Corporation | 697.71 Thousand USD | 87.817% |
| Titan Pharmaceuticals, Inc. | - USD | -Infinity% |
| Achieve Life Sciences, Inc. | 6000.00 USD | -1316.667% |
| BeiGene, Ltd. | 197.61 Million USD | 99.957% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | 90.675% |
| Revolution Medicines, Inc. Warrant | 80.57 Million USD | 99.895% |
| Protagonist Therapeutics, Inc. | - USD | -Infinity% |
| Erasca, Inc. | 51.88 Million USD | 99.836% |
| bluebird bio, Inc. | 224.41 Million USD | 99.962% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 99.986% |
| DBV Technologies S.A. | 4.52 Million USD | 98.122% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | - USD | -Infinity% |
| Vincerx Pharma, Inc. | 1.34 Million USD | 93.657% |
| Fresh Tracks Therapeutics, Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 9.74 Million USD | 99.127% |
| Acrivon Therapeutics, Inc. Common Stock | 3.76 Million USD | 97.744% |
| Travere Therapeutics, Inc. | 377.26 Million USD | 99.977% |
| Monte Rosa Therapeutics, Inc. | 42.87 Million USD | 99.802% |
| Spruce Biosciences, Inc. | 1.71 Million USD | 95.05% |
| Celldex Therapeutics, Inc. | 928 Thousand USD | 90.841% |
| Cogent Biosciences, Inc. | 17.46 Million USD | 99.513% |
| MacroGenics, Inc. | 30.19 Million USD | 99.719% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | 17.7 Million USD | 99.52% |
| Prime Medicine, Inc. | 4.35 Million USD | 98.049% |
| Aditxt, Inc. | 1.04 Million USD | 91.841% |
| Adagene Inc. | 13.54 Million USD | 99.372% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 99.381% |
| Maravai LifeSciences Holdings, Inc. | 518.7 Million USD | 99.984% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 17.09 Million USD | 99.503% |
| SciSparc Ltd. | 24 Thousand USD | -254.167% |
| Vericel Corporation | 81.85 Million USD | 99.896% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | 82.01 Million USD | 99.896% |
| Generation Bio Co. | 89.77 Million USD | 99.905% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | 22.18 Million USD | 99.617% |
| Arcutis Biotherapeutics, Inc. | 201.79 Million USD | 99.958% |
| Invivyd, Inc. | 722 Thousand USD | 88.227% |
| Relay Therapeutics, Inc. | 48.5 Million USD | 99.825% |
| Quoin Pharmaceuticals, Ltd. | 2923.73 USD | -2807.245% |
| Spero Therapeutics, Inc. | 3.82 Million USD | 97.778% |
| Artelo Biosciences, Inc. | 23 Thousand USD | -269.565% |
| 2seventy bio, Inc. | 244.01 Million USD | 99.965% |
| ADMA Biologics, Inc. | 130.59 Million USD | 99.935% |
| Clene Inc. | 7.15 Million USD | 98.812% |
| Capricor Therapeutics, Inc. | 3.37 Million USD | 97.482% |
| Boundless Bio, Inc. Common Stock | 247.61 Million USD | 99.966% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 1.1 Million USD | 92.28% |
| Citius Pharmaceuticals, Inc. | 262.86 Thousand USD | 67.664% |
| Contineum Therapeutics, Inc. Class A Common Stock | 192.62 Million USD | 99.956% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | 99.701% |
| ALX Oncology Holdings Inc. | 9.63 Million USD | 99.118% |
| Vir Biotechnology, Inc. | 111.67 Million USD | 99.924% |
| Evaxion Biotech A/S | 8.48 Million USD | 98.999% |
| Ocular Therapeutix, Inc. | 74.92 Million USD | 99.887% |
| Verve Therapeutics, Inc. | 64.71 Million USD | 99.869% |
| Trevena, Inc. | 35.23 Million USD | 99.759% |
| Surrozen, Inc. | 882 Thousand USD | 90.363% |
| Tyra Biosciences, Inc. | 6.21 Million USD | 98.633% |
| Cingulate Inc. | 135.09 Thousand USD | 37.083% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | 23.53 Million USD | 99.639% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 47.8 Million USD | 99.822% |
| Connect Biopharma Holdings Limited | 180 Thousand USD | 52.778% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 25.37 Million USD | 99.665% |
| Bolt Biotherapeutics, Inc. | 17.43 Million USD | 99.513% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | 936 Thousand USD | 90.919% |
| Statera Biopharma, Inc. | 11.43 Million USD | 99.256% |
| ImmunityBio, Inc. | 836.95 Million USD | 99.99% |
| Korro Bio, Inc. | 31.21 Million USD | 99.728% |
| Kineta, Inc. | 150 Thousand USD | 43.333% |
| BioVie Inc. | 349.89 Thousand USD | 75.707% |
| Codexis, Inc. | 12.24 Million USD | 99.306% |
| Celularity Inc. | 26.17 Million USD | 99.675% |
| Crinetics Pharmaceuticals, Inc. | 47.55 Million USD | 99.821% |
| Celcuity Inc. | 37.03 Million USD | 99.77% |
| Virax Biolabs Group Limited | 176.34 Thousand USD | 51.799% |
| Cibus, Inc. | 17.67 Million USD | 99.519% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | 3.37 Million USD | 97.484% |
| Kodiak Sciences Inc. | 100 Million USD | 99.915% |
| Annexon, Inc. | 29.19 Million USD | 99.709% |
| Adverum Biotechnologies, Inc. | 64.62 Million USD | 99.868% |
| Assembly Biosciences, Inc. | 1.12 Million USD | 92.424% |
| Avalo Therapeutics, Inc. | 2 Million USD | 95.75% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 99.994% |
| Eyenovia, Inc. | 8.95 Million USD | 99.051% |
| Puma Biotechnology, Inc. | 65.65 Million USD | 99.871% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | 8.14 Million USD | 98.956% |
| Arcellx, Inc. | 50.84 Million USD | 99.833% |
| Cardiff Oncology, Inc. | 1.45 Million USD | 94.17% |
| Enanta Pharmaceuticals, Inc. | 21.23 Million USD | 99.6% |
| Regulus Therapeutics Inc. | 1.05 Million USD | 91.943% |
| Moolec Science SA | 99.04 Thousand USD | 14.181% |
| Acumen Pharmaceuticals, Inc. | 27.62 Million USD | 99.692% |
| Geron Corporation | 35.05 Million USD | 99.757% |
| LAVA Therapeutics N.V. | 591 Thousand USD | 85.618% |
| Royalty Pharma plc | 6.13 Billion USD | 99.999% |
| Atea Pharmaceuticals, Inc. | 1.64 Million USD | 94.823% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 31.74 Thousand USD | -167.784% |
| Mersana Therapeutics, Inc. | 23.14 Million USD | 99.633% |
| Humacyte, Inc. | 38.6 Million USD | 99.78% |
| Structure Therapeutics Inc. | 4.01 Million USD | 97.882% |
| 89bio, Inc. | 24.79 Million USD | 99.657% |
| PMV Pharmaceuticals, Inc. | 12.43 Million USD | 99.316% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 1.86 Million USD | 95.445% |
| Trevi Therapeutics, Inc. | 1.03 Million USD | 91.764% |
| Lexicon Pharmaceuticals, Inc. | 99.5 Million USD | 99.915% |
| Notable Labs, Ltd. | 1.52 Million USD | 94.43% |
| Liquidia Corporation | 2.36 Million USD | 96.404% |
| Mustang Bio, Inc. | 1.97 Million USD | 95.703% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 13.73 Million USD | 99.381% |
| Arbutus Biopharma Corporation | 6.95 Million USD | 98.778% |
| DiaMedica Therapeutics Inc. | 317 Thousand USD | 73.186% |
| Vera Therapeutics, Inc. | 49.87 Million USD | 99.83% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | 9.6 Million USD | 99.115% |
| Elevai Labs, Inc. Common Stock | 65.48 Thousand USD | -29.793% |
| NeuroBo Pharmaceuticals, Inc. | 136 Thousand USD | 37.5% |
| Tempest Therapeutics, Inc. | 6.26 Million USD | 98.643% |
| Soleno Therapeutics, Inc. | 130 Thousand USD | 34.615% |
| PepGen Inc. | 17.1 Million USD | 99.503% |
| Moleculin Biotech, Inc. | 474 Thousand USD | 82.068% |
| United Therapeutics Corporation | 300 Million USD | 99.972% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | 23.94 Million USD | 99.645% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | 4.16 Million USD | 97.958% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | 578 Thousand USD | 85.294% |
| XOMA Corporation | 118.51 Million USD | 99.928% |
| ARS Pharmaceuticals, Inc. | 37 Thousand USD | -129.73% |
| Bionomics Limited | 117.62 Million USD | 99.928% |
| Apogee Therapeutics, Inc. | 933 Thousand USD | 90.89% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 98.485% |
| uniQure N.V. | 130.06 Million USD | 99.935% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 58.59 Million USD | 99.855% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | 686 Thousand USD | 87.609% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | 4.33 Million USD | 98.04% |
| FibroBiologics, Inc. Common Stock | 1.38 Million USD | 93.863% |
| Altimmune, Inc. | 175 Thousand USD | 51.429% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 99.978% |
| Alpha Tau Medical Ltd. | 5.61 Million USD | 98.485% |
| Compugen Ltd. | 719 Thousand USD | 88.178% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Zevra Therapeutics, Inc. | 5.06 Million USD | 98.322% |
| Benitec Biopharma Inc. | - USD | -Infinity% |
| Spyre Therapeutics, Inc. | 84.55 Million USD | 99.899% |
| NKGen Biotech, Inc. Common Stock | 9.93 Million USD | 99.144% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | 6.37 Million USD | 98.668% |
| Aileron Therapeutics, Inc. | 91.41 Million USD | 99.907% |
| NKGen Biotech, Inc. Warrants | 9.93 Million USD | 99.144% |
| Instil Bio, Inc. | 81.42 Million USD | 99.896% |
| argenx SE | 15.35 Million USD | 99.446% |
| Immunome, Inc. | 1.34 Million USD | 93.657% |
| Compass Therapeutics, Inc. | 536 Thousand USD | 84.142% |
| Verona Pharma plc | 48.37 Million USD | 99.824% |
| enGene Holdings Inc. Warrants | 9.21 Million USD | 99.078% |
| Shattuck Labs, Inc. | 3.4 Million USD | 97.504% |
| CervoMed Inc. | - USD | -Infinity% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Dianthus Therapeutics, Inc. | 168 Thousand USD | 49.405% |
| Moolec Science SA | 99.04 Thousand USD | 14.181% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 11.03 Million USD | 99.23% |
| AnaptysBio, Inc. | 16.03 Million USD | 99.47% |
| Design Therapeutics, Inc. | 2.33 Million USD | 96.358% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 27.07 Thousand USD | -213.989% |
| Seelos Therapeutics, Inc. | - USD | -Infinity% |
| Lumos Pharma, Inc. | 6 Million USD | 98.583% |
| Achilles Therapeutics plc | 1.07 Million USD | 92.1% |
| enGene Holdings Inc. Common Stock | 9.21 Million USD | 99.078% |
| 180 Life Sciences Corp. | 19.93 Thousand USD | -326.364% |
| Opiant Pharmaceuticals, Inc. | 16.74 Million USD | 99.492% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 79.82 Thousand USD | -6.482% |
| ORIC Pharmaceuticals, Inc. | 7461.00 USD | -1039.257% |
| CG Oncology, Inc. Common stock | 13 Thousand USD | -553.846% |
| Fractyl Health, Inc. Common Stock | 342.48 Million USD | 99.975% |
| Rani Therapeutics Holdings, Inc. | 24.48 Million USD | 99.653% |
| MoonLake Immunotherapeutics | 2.49 Million USD | 96.6% |
| Palisade Bio, Inc. | 90 Thousand USD | 5.556% |
| Tourmaline Bio, Inc. | 194 Thousand USD | 56.186% |
| Beam Therapeutics Inc. | 159.91 Million USD | 99.947% |
| Neurogene Inc. | 13.37 Million USD | 99.364% |
| Mirum Pharmaceuticals, Inc. | 306.42 Million USD | 99.972% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | 26.26 Million USD | 99.676% |
| Sesen Bio, Inc. | - USD | -Infinity% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | 59.82 Thousand USD | -42.088% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | 91.5% |
| Taysha Gene Therapies, Inc. | 40.5 Million USD | 99.79% |
| Athira Pharma, Inc. | 1.21 Million USD | 93.016% |
| Vaccinex, Inc. | 26 Thousand USD | -226.923% |
| HCW Biologics Inc. | 6.3 Million USD | 98.652% |
| XOMA Corporation | 118.51 Million USD | 99.928% |
| Nektar Therapeutics | 112.62 Million USD | 99.925% |
| Arvinas, Inc. | 800 Thousand USD | 89.375% |
| Tevogen Bio Holdings Inc. | 14.45 Million USD | 99.412% |
| Merus N.V. | 10.48 Million USD | 99.19% |
| Omega Therapeutics, Inc. | 14.88 Million USD | 99.429% |
| Quince Therapeutics, Inc. | 13.42 Million USD | 99.367% |
| Rezolute, Inc. | 1.66 Million USD | 94.88% |
| Clene Inc. | 7.15 Million USD | 98.812% |
| Indaptus Therapeutics, Inc. | 73.34 Thousand USD | -15.886% |
| BeyondSpring Inc. | 3.36 Million USD | 97.473% |
| Synlogic, Inc. | 12.49 Million USD | 99.32% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | - USD | -Infinity% |
| Werewolf Therapeutics, Inc. | 32.65 Million USD | 99.74% |
| Krystal Biotech, Inc. | 6.62 Million USD | 98.716% |
| Karyopharm Therapeutics Inc. | 170.91 Million USD | 99.95% |
| SpringWorks Therapeutics, Inc. | 5.99 Million USD | 98.582% |
| Lipella Pharmaceuticals Inc. | 47.37 Thousand USD | -79.435% |
| MannKind Corporation | 252.15 Million USD | 99.966% |
| Ikena Oncology, Inc. | 7.18 Million USD | 98.816% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 199 Thousand USD | 57.286% |
| Gossamer Bio, Inc. | 197.4 Million USD | 99.957% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | 520 Thousand USD | 83.654% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 281.32 Million USD | 99.97% |
| Mural Oncology plc | 8.91 Million USD | 99.046% |
| Biora Therapeutics, Inc. | 43.73 Million USD | 99.806% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | 1.43 Million USD | 94.081% |
| Champions Oncology, Inc. | 6.09 Million USD | 98.605% |
| REGENXBIO Inc. | 82.22 Million USD | 99.897% |
| Ensysce Biosciences, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | 494 Thousand USD | 82.794% |
| Edgewise Therapeutics, Inc. | 4.43 Million USD | 98.083% |
| Vaxart, Inc. | 2.62 Million USD | 96.759% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | 271.63 Thousand USD | 68.708% |
| Cellectis S.A. | 36.24 Million USD | 99.765% |
| Longeveron Inc. | 1.44 Million USD | 94.13% |
| Repare Therapeutics Inc. | 1.01 Million USD | 91.584% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 99.992% |
| Inozyme Pharma, Inc. | 44.76 Million USD | 99.81% |
| Revolution Medicines, Inc. | 80.57 Million USD | 99.895% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | 3.2 Million USD | 97.35% |
| ArriVent BioPharma, Inc. Common Stock | 177 Thousand USD | 51.977% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 123 Thousand USD | 30.894% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 99.988% |
| Denali Therapeutics Inc. | 44.98 Million USD | 99.811% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 12.5 Million USD | 99.32% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | 135.09 Thousand USD | 37.083% |
| Passage Bio, Inc. | 22.92 Million USD | 99.629% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | 6.03 Million USD | 98.592% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 647 Thousand USD | 86.862% |
| Scinai Immunotherapeutics Ltd. | 20.16 Million USD | 99.578% |
| Rhythm Pharmaceuticals, Inc. | 490 Thousand USD | 82.653% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 407.45 Thousand USD | 79.139% |
| Carisma Therapeutics, Inc. | 1.18 Million USD | 92.845% |
| Unicycive Therapeutics, Inc. | 466 Thousand USD | 81.76% |
| OmniAb, Inc. | 22.07 Million USD | 99.615% |
| Anew Medical, Inc. | 1.54 Million USD | 94.481% |
| Fennec Pharmaceuticals Inc. | 29.55 Million USD | 99.712% |
| Lipocine Inc. | - USD | -Infinity% |
| Lexeo Therapeutics, Inc. Common Stock | 9.03 Million USD | 99.059% |
| Nautilus Biotechnology, Inc. | 31.09 Million USD | 99.727% |
| SAB Biotherapeutics, Inc. | 4.05 Million USD | 97.903% |
| G1 Therapeutics, Inc. | 51.55 Million USD | 99.835% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | - USD | -Infinity% |
| Ocugen, Inc. | 6.36 Million USD | 98.665% |
| Mind Medicine (MindMed) Inc. | 14.12 Million USD | 99.398% |
| Q32 Bio Inc. | - USD | -Infinity% |
| Brainstorm Cell Therapeutics Inc. | 672 Thousand USD | 87.351% |
| Alumis Inc. Common Stock | 30.86 Million USD | 99.725% |
| Equillium, Inc. | 384 Thousand USD | 77.865% |
| Kyverna Therapeutics, Inc. | 6.15 Million USD | 98.62% |
| Coya Therapeutics, Inc. | - USD | -Infinity% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 99.944% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 99.826% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | 29.344% |
| Dominari Holdings Inc. | 3.02 Million USD | 97.193% |
| Edesa Biotech, Inc. | 19.77 Thousand USD | -329.879% |
| vTv Therapeutics Inc. | 169 Thousand USD | 49.704% |
| Bio-Techne Corporation | 319 Million USD | 99.973% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 99.851% |
| Harmony Biosciences Holdings, Inc. | 178.56 Million USD | 99.952% |
| Prelude Therapeutics Incorporated | 15.4 Million USD | 99.448% |
| Candel Therapeutics, Inc. | 12.38 Million USD | 99.314% |
| iTeos Therapeutics, Inc. | 4.8 Million USD | 98.232% |
| Nkarta, Inc. | 82.27 Million USD | 99.897% |
| BioCardia, Inc. | 982 Thousand USD | 91.344% |
| Iterum Therapeutics plc | 18.95 Million USD | 99.552% |